PTPRC and neoplasm: Despite the low baseline abundance of CD4+ and CD8α+ T cells in tumors (<1% of CD45+ cells; Fig. 1C), treatment with anti‐mPD‐1 mAb significantly delayed both tumor progression and recurrence (Figs. 2, 3).